Shekkeris A S, Hanna S A, Sewell M D, Spiegelberg B G I, Aston W J S, Blunn G W, Cannon S R, Briggs T W R
Royal National Orthopaedic Hospital, Stanmore, Middlesex, England.
J Bone Joint Surg Br. 2009 Oct;91(10):1378-82. doi: 10.1302/0301-620X.91B10.22643.
Endoprosthetic replacement of the distal tibia and ankle joint for a primary bone tumour is a rarely attempted and technically challenging procedure. We report the outcome of six patients treated between 1981 and 2007. There were four males and two females, with a mean age of 43.5 years (15 to 75), and a mean follow-up of 9.6 years (1 to 27). No patient developed a local recurrence or metastasis. Two of the six went on to have a below-knee amputation for persistent infection after a mean 16 months (1 to 31). The four patients who retained their endoprosthesis had a mean musculoskeletal tumour society score of 70% and a mean Toronto extremity salvage score of 71%. All were pain free and able to perform most activities of daily living in comfort. A custom-made endoprosthetic replacement of the distal tibia and ankle joint is a viable treatment option for carefully selected patients with a primary bone tumour. Patients should, however, be informed of the risk of infection and the potential need for amputation if this cannot be controlled.
采用内置假体置换治疗原发性骨肿瘤累及胫骨远端和踝关节是一种很少尝试且技术上具有挑战性的手术。我们报告了1981年至2007年间接受治疗的6例患者的治疗结果。其中男性4例,女性2例,平均年龄43.5岁(15至75岁),平均随访9.6年(1至27年)。无患者出现局部复发或转移。6例中有2例在平均16个月(1至31个月)后因持续性感染而接受了膝下截肢。保留内置假体的4例患者的肌肉骨骼肿瘤学会平均评分为70%,多伦多肢体挽救平均评分为71%。所有患者均无疼痛,能够舒适地进行大多数日常生活活动。对于精心挑选的原发性骨肿瘤患者,定制的胫骨远端和踝关节内置假体置换是一种可行的治疗选择。然而,应告知患者感染风险以及如果感染无法控制可能需要截肢的情况。